C3 Glomerulopathy

A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Fabhalta Capsules Specified Drug-use Survey

Study of NM8074 in Adult C3 Glomerulopathy Patients

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

CHART-C3G/CLNP023B12011

C3G/Primary IC-MPGN EAP

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Home Reported Outcomes in C3G Study

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

National Registry of Rare Kidney Diseases

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN